Healthcare Industry News: TrueBeam
News Release - August 11, 2011
Elekta Deepens Integration of MOSAIQ Oncology Information System with Varian TrueBeam Radiotherapy Delivery SystemUsers of Varian flagship system gain new MOSAIQ functionality
ATLANTA, Aug. 11, 2011 -- (Healthcare Sales & Marketing Network) -- The seamless integration of Elekta's MOSAIQ® Oncology Information System (OIS)* and Varian's TrueBeam™ radiation therapy system is enabling the introduction of new OIS functionality, such as flattening filter free definition, delivery and alerts and enhanced communication capabilities. Numerous TrueBeam users have connected with MOSAIQ since the interface was introduced in 2010, and increasing numbers of users are expected to make MOSAIQ their OIS. The MOSAIQ interface to TrueBeam exemplifies the unparalleled integration between MOSAIQ and the radiation therapy systems of other providers, such as Siemens and Accuray/TomoTherapy, and particle therapy vendors, such as Hitachi and IBA.
"Integrating MOSAIQ and TrueBeam was only the critical first step," says Todd Powell, Executive Vice President, Elekta Software. "This connectivity has facilitated ongoing additional functionality that we're pleased to offer to TrueBeam users as they strive to improve patient care."
The MOSAIQ OIS streamlines medical oncology and radiation oncology workflows from the first encounter, through diagnosis and staging, planning, treatment and long-term follow-up. At the heart of MOSAIQ is the image-enabled EMR, through which healthcare providers communicate information about their patients during the cancer management continuum.
The work-in-progress MOSAIQ functionality for TrueBeam users will include:
- Characterization of stereotactic cones: In MOSAIQ, TrueBeam users will be able to specify field size limitations and other parameters of stereotactic cones and transmit to the linac console.
- Full support of complex SRS treatments, including complicated deliveries. The MOSAIQ interface enables dose verification at the TrueBeam console prior to delivery.
- Multi-frame imaging, such as fluoro imaging.
- Gating alerts: MOSAIQ will flag the linear accelerator's control system that a particular patient has been prescribed gated therapy delivery.
Leveraging more than 20 years of leadership and expertise of IMPAC Medical Systems, MOSAIQ continues to set the standard for connectivity and usability in the most advanced cancer care facilities in the world. From its multiple redundant safety features to industry-leading practice management capabilities, MOSAIQ is the tool of choice to manage cutting-edge treatment centers, and is the first comprehensive OIS to receive complete EMR certification. Complete EMR certification enables U.S. providers to qualify to demonstrate Stage 1 meaningful use under the HITECH Act.
*MOSAIQ® is a registered trademark of its manufacturer, IMPAC Medical Systems, Inc. SEQUENCER is MOSAIQ's verify & record module.
Elekta is a human care company pioneering significant innovations and clinical solutions for treating cancer and brain disorders. The company develops sophisticated, state-of-the-art tools and treatment planning systems for radiation therapy and radiosurgery, as well as workflow enhancing software systems across the spectrum of cancer care.
Stretching the boundaries of science and technology, providing intelligent and resource-efficient solutions that offer confidence to both healthcare providers and patients, Elekta aims to improve, prolong and even save patient lives, making the future possible.
Today, Elekta solutions in oncology and neurosurgery are used in over 5,000 hospitals globally, and every day more than 100,000 patients receive diagnosis, treatment or follow-up with the help of a solution from the Elekta Group.
Elekta employs around 2,500 employees globally. The corporate headquarter is located in Stockholm, Sweden, and the company is listed on the Nordic Exchange under the ticker EKTAb. For more information about Elekta, please visit www.elekta.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.